Congenital erythropoietic porphyria (CEP) is a rare form of porphyria caused by impaired activity of the enzyme responsible for the forth step of heme synthesis (uroporphyrinogen III synthase or ferrochelatase). The main affected organ is the skin because the substrate (protoporphyrin) accumulates excessively in the body, particularly the skin, and causes distinctive cutaneous photosensitivity. Exposing the skin to sunlight will develop severe blistering, infections, scarring, changes in pigmentation, and increased hair growth. Also, anemia due to low number of RBC, splenomegaly, and a hepatobiliary disease are common manifestations in CEP. The disease may start during early infancy or even during the intrauterine period; however, certain cases develop the symptoms in childhood or adulthood. It is noted that the latent the disease starts, the milder the symptoms are. Reports have shown less than 200 cases of CEP worldwide with equal distribution among both males and females.
Congenital erythropoietic porphyria (CEP) is transmitted as an autosomal recessive trait. Mutations in the uroporphyrinogen III synthase (UROS) gene cause the symptoms of CEP.